Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Litigation Aside Biosimilar Avastin Just Got Cheaper In India

Executive Summary

Another biosimilar version of Roche's anticancer, Avastin (bevacizumab) has just arrived on the Indian market despite the shadow of ongoing litigation. The launch, cheered by some activists, takes prices of biosimilar bevacizumab lower, amid allegations that Roche has been pursuing "vexatious" litigation against Indian competitors.


Related Content

Biocon’s Avastin Biosimilar To Put The Heat On Competition?
Indian Avastin Biosimilar Arrives Amid Roche's Charges
Indian Avastin Versions Head For Debut; Watch Off-Label Space
Roche draws emerging markets battle lines with launch of cut-price Herceptin and MabThera in India


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts